Effective prophylactic treatments of migraine lower plasma glutamate levels

Cephalalgia

Volumn 29, Issue 4, 2009, Pages 423-429

  Ferrari, A ^a,b   Spaccapelo, L ^b   Pinetti, D ^b   Tacchi, R ^b   Bertolini, A ^b  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Glutamate; Level; Migraine; Prophylaxis; Treatment

Indexed keywords

AMITRIPTYLINE; FLUNARIZINE; GLUTAMIC ACID; PROPRANOLOL; TOPIRAMATE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIET RESTRICTION; DISEASE CLASSIFICATION; FEMALE; FLUOROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MIGRAINE; PROPHYLAXIS;

ADULT; ANALGESICS; FEMALE; GLUTAMIC ACID; HUMANS; MALE; MIGRAINE DISORDERS; YOUNG ADULT;

EID: 61849185958     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2008.01749.x     Document Type: Article

References (44)

1. Jensen R, Stovner LJ. Epidemiology and comorbidity of headache. Lancet Neurol 2008 7 : 354 61.
2. Meng ID, Cao L. From migraine to chronic daily headache: the biological basis of headache transformation. Headache 2007 47 : 1251 8.
3. Bigal ME, Lipton RB. Concepts and mechanisms of migraine chronification. Headache 2008 48 : 7 15.
4. Kurth T, Gaziano JM, Cook NR, Logroscino G, Diener HC, Buring JE. Migraine and risk of cardiovascular disease in women. JAMA 2006 296 : 283 91.
5. Kurth T, Gaziano JM, Cook NR, Bubes V, Logroscino G, Diener HC, Buring JE. Migraine and risk of cardiovascular disease in men. Arch Intern Med 2007 167 : 795 801.
6. MacClellan RL, Giles W, Cole J, Wozniak M, Stern B, Mitchell BD, Kittner SJ. Probable migraine with visual aura and risk of ischemic stroke: the stroke prevention in young women study. Stroke 2007 38 : 2438 45.
7. Krymchantowsky AV, Rapoport AM, Jevoux CC. The future of acute care and prevention in headache. Neurol Sci 2007 28 (Suppl. 2 S166 78.
8. Schürks M, Diener HC, Goadsby P. Update on the prophylaxis of migraine. Curr Treat Options Neurol 2008 10 : 20 9.
9. Ramadan NM. The link between glutamate and migraine. CNS Spectr 2003 8 : 446 9.
10. Baltan S, Besancon EF, Mbow B, Ye Z, Hamner MA, Ransom BR. White matter vulnerability to ischemic injury increases with age because of enhanced excitotoxicity. J Neurosci 2008 28 : 1479 89.
11. Shigeri Y, Seal RP, Shimamoto K. Molecular pharmacology of glutamate transporters, EAATs and VGLUTs. Brain Res Brain Res Rev 2004 45 : 250 65.
12. Moskowitz MA, Macfarlane R. Neurovascular and molecular mechanisms in migraine headaches. Cerebrovasc Brain Metab Rev 1993 5 : 159 77.
13. Goadsby PJ, Classey JD. Glutamatergic transmission in the trigeminal nucleus assessed with local blood flow. Brain Res 2000 875 : 119 24.
14. Oshinsky ML, Luo J. Neurochemistry of trigeminal activation in an animal model of migraine. Headache 2006 46 (Suppl. 1 S39 44.
15. Ferrari MD, Odink J, Bos KD, Malessy MJ, Bruyn GW. Neuroexcitatory plasma amino acids are elevated in migraine. Neurology 1990 40 : 1582 6.
16. D'Andrea G, Cananzi AR, Joseph R, Morra M, Zamberlan F, Ferro Milone F et al. Platelet glycine, glutamate and aspartate in primary headache. Cephalalgia 1991 11 : 197 200.
17. Martínez F, Castillo J, Rodríguez JR, Leira R, Noya M. Neuroexcitatory amino acid levels in plasma and cerebrospinal fluid during migraine attacks. Cephalalgia 1993 13 : 89 93.
18. Cananzi AR, D'Andrea G, Perini F, Zamberlan F, Welch KM. Platelet and plasma levels of glutamate and glutamine in migraine with and without aura. Cephalalgia 1995 15 : 132 5.
19. Alam Z, Coombes N, Waring RH, Williams AC, Steventon GB. Plasma levels of neuroexcitatory amino acids in patients with migraine or tension headache. J Neurol Sci 1998 156 : 102 6.
20. Rajda C, Tajti J, Komoróczy R, Seres E, Klivényi P, Vécsei L. Amino acids in the saliva of patients with migraine. Headache 1999 39 : 644 9.
21. Peres MF, Zukerman E, Senne Soares CA, Alonso EO, Santos BF, Faulhaber MH. Cerebrospinal fluid glutamate levels in chronic migraine. Cephalalgia 2004 24 : 735 9.
22. Vieira DS, Naffah-Mazzacoratti MG, Zukerman E, Senne Soares CA, Cavalheiro EA, Peres MF. Glutamate levels in cerebrospinal fluid and triptans overuse in chronic migraine. Headache 2007 47 : 842 7.
23. Vaccaro M, Riva C, Tremolizzo L, Longoni M, Aliprandi A, Agostani E et al. Platelet glutamate uptake and release in migraine with and without aura. Cephalalgia 2007 27 : 35 40.
24. Gonzalez de la Aleja J, Porta-Etessam J, Sepulveda-Sanchez JM, Rodriguez Pena-Marin M. The pathophysiology of migraine. Reflections on the glutamatergic hypothesis. Rev Neurol 2006 43 : 481 8.
25. Headache Classification Subcommittee of International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004 24 (Suppl. 1 S9 160.
26. Georgi G, Pietsch C, Sawatzki G. High-performance liquid chromatographic determination of amino acids in protein hydrolysates and in plasma using automated pre-column derivatization with o-phthaldialdehyde/2-mercaptoethanol. J Chromatogr 1993 613 : 35 42.
27. Normann G, Streiner D. Biostatistics. The bare essentials, 2nd edn. Ontario : BC Decker Inc. 2000.
28. Vikelis M, Mitsikostas DD. The role of glutamate and its receptors in migraine. CNS Neurol Disord Drug Targets 2007 6 : 251 7.
29. van den Maagdenberg AM, Haan J, Terwindt GM, Ferrari MD. Migraine: gene mutations and functional consequences. Curr Opin Neurol 2007 20 : 299 305.
30. Kaniecki R. Neuromodulators for migraine prevention. Headache 2008 48 : 586 600.
31. Ayata C, Jin H, Kudo C, Dalkara T, Moskowitz MA. Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol 2006 59 : 652 61.
32. Cousin MA, Nicholls DG, Pocock JM. Flunarizine inhibits both calcium-dependent and -independent release of glutamate from synaptosomes and cultured neurones. Brain Res 1993 606 : 227 36.
33. Mangano RM, Schwarcz R. Platelet glutamate and aspartate uptake in Huntington's disease. J Neurochem 1981 37 : 1072 4.
34. Tremolizzo L, Di Francesco JC, Rodriguez-Menendez V, Sirtori E, Longoni M, Cassetti A et al. Human platelets express the synaptic markers VGLUT1 and 2 and release glutamate following aggregation. Neurosci Lett 2006 404 : 262 5.
35. Taffi R, Vignini A, Lanciotti C, Luconi R, Nanetti L, Mazzanti L. Platelet membrane fluidity and peroxynitrite levels in migraine patients during headache-free periods. Cephalalgia 2005 25 : 353 8.
36. Zeller JA, Lindner V, Frahm K, Baron R, Deuschl G. Platelet activation and platelet-leucocyte interaction in patients with migraine. Subtype differences and influence of triptans. Cephalalgia 2005 25 : 536 41.
37. Smith QR. Transport of glutamate and other amino acids at the blood-brain barrier. J Nutr 2000 130 (Suppl. 4 S1016 22.
38. Bogdanov MB, Wurtman RJ. Effects of systemic or oral ad libitum monosodium glutamate administration on striatal glutamate release, as measured using microdialysis in freely moving rats. Brain Res 1994 660 : 337 40.
39. Friedman A, Kaufer D, Shemer J, Hendler I, Soreq H, Tur-Kaspa I. Pyridostigmine brain penetration under stress enhances neuronal excitability and induces early immediate transcriptional response. Nat Med 1996 2 : 1382 5.
40. Tomkins O, Kaufer D, Korn A, Shelef I, Golan H, Reichenthal E et al. Frequent blood-brain barrier disruption in the human cerebral cortex. Cell Mol Neurobiol 2001 21 : 675 91.
41. Gursoy-Ozdemir Y, Qiu J, Matsuoka N, Bolay H, Bermpohl D, Jin H et al. Cortical spreading depression activates and upregulates MMP-9. J Clin Invest 2004 113 : 1447 55.
42. Leira R, Sobrino T, Rodriguez-Yanez M, Blanco M, Arias S, Castillo J. Mmp-9 immunoreactivity in acute migraine. Headache 2007 47 : 698 702.
43. Imamura K, Takeshima T, Fusayasu E, Nakashima K. Increased plasma matrix metalloproteinase-9 levels in migraineurs. Headache 2008 48 : 135 9.
44. Aurora SK, Wilkinson F. The brain is hyperexcitable in migraine. Cephalalgia 2007 27 : 1442 53.